Why is FibroGen, Inc. ?
- Poor long term growth as Net Sales has grown by an annual rate of -41.32% and Operating profit at 12.94% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -93.57
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -26.83%, its profits have risen by 76.5%
- Along with generating -26.83% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is FibroGen, Inc. for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At USD 2.42 MM has Grown at 116.24%
Highest at USD -16.97 MM
Fallen by -119.63% (YoY
Highest at USD -5.18 MM
Highest at USD -6.52 MM
Highest at USD -6.52 MM
Highest at USD 36.71
At USD 5.16 MM has Grown at -80.51%
Lowest at USD 141.34 MM
Highest at 569.27 %
Lowest at -0.32 times
Lowest at 0.18 times
Here's what is working for FibroGen, Inc.
Net Sales (USD MM)
Operating Cash Flows (USD MM)
Operating Profit (USD MM)
Pre-Tax Profit (USD MM)
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
Net Profit (USD MM)
EPS (USD)
Raw Material Cost as a percentage of Sales
Here's what is not working for FibroGen, Inc.
Cash and Cash Equivalents
Debt-Equity Ratio
Inventory Turnover Ratio
Debtors Turnover Ratio






